跳至主要内容
临床试验/NCT02528448
NCT02528448Unknown4 期

The Effect of 0,9% NaCl on the Kidney Function, Vasoactive Hormones, Biomarkers and Glycosaminglycanes in Plasma in Patients Operated on for Primary Hiparthrosis

Regional Hospital Holstebro1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
40
试验地点
1
主要终点
Urinary excretion of Neutrophil gelatinase-associated lipocalin

研究概览

简要总结

The purpose of this study is to determine if chloride is nephrotoxic using 0,9% saline versus Plasma-Lytein in patients having primary hip replacement surgery. The outcome is found measuring bio markers, vasoactive hormones and salt regulation. And to measure syndecan as a marker for glycocalyx degradation.

详细描述

Hypothesis:

Chloride has a nephrotoxic effect, which can be shown partially by measuring bio markers for tubular injury in urine, partially by the changes in tubular transport of sodium and water in different parts of the nephron. This can be demonstrated using isotone sodium solutions with a lower chloride concentration in this study plasma-lyte versus normal isotone saline.

Klorid has a toxic effect on the glycocalyx layer and leads to a rise in syndecan 1 and simultaneously a change in Salt Blood Test either by a direct simulation and ANP levels in plasma or as a consequence of the hyperchloremic acidosis. This can be demonstrated using isotone sodium solutions with a lower chloride concentration in this study plasma-lyte versus normal isotone saline.

Purpose:

The purpose is to observe changes in bio markers, vasoactive hormones and salt regulation in patients randomized to either 0,9% saline or plasma-lyte undergoing primary uncemented hip replacement surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Indication for uncemented primary hiparthroplasty
  • age < 60

排除标准

  • Blooddonation or transfusion during the last month
  • Not willing to participate
  • estimated GFR below 30ml/min
  • type 1 diabetes

研究组 & 干预措施

plasma-lyte

Active Comparator

Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement

干预措施: Plasma-lyte (Drug)

0,9% saline

Active Comparator

Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement

干预措施: 0,9% saline (Drug)

结局指标

主要结局

Urinary excretion of Neutrophil gelatinase-associated lipocalin

时间窗: two days

次要结局

  • Urinary excretion of Kidney Injury Molecule(two days)
  • Plasma concentration of angiotensin 2(two days)
  • Plasma concentration of atrial natriuretic peptide (ANP)(two days)
  • Plasma concentration of brain natriuretic peptide (BNP)(two days)
  • Plasma osmolarity(two days)
  • plasma Syndecan-1(two days)
  • Urinary excretion of epithelial sodium channels(two days)
  • Urinary excretion of Fatty acid-binding protein(two days)
  • Plasma concentration of chloride(two days)
  • plasma renin concentration(two days)
  • Urinary excretion of cyclic guanosine monophosphate(two days)
  • Plasma concentration of vasopressin (AVP, ADH)(two days)
  • Free water clearance(two days)
  • Plasma concentration of albumin(two days)
  • Plasma concentration of sodium(two days)
  • Urinary excretion of chloride(two days)
  • Urinary excretion of potassium(two days)
  • Fractional urinary sodium excretion(two days)
  • Urinary excretion of albumin(two days)
  • Urinary excretion of water channels(two days)
  • Plasma concentration of aldosterone(two days)
  • Plasma concentration of cyclic guanosine monophosphate (cGMP)(two days)
  • Plasma concentration of endothelin(two days)
  • Plasma concentration of creatinine(two days)
  • pH(two days)
  • Plasma concentration of potassium(two days)
  • Urinary excretion of creatinine(two days)
  • Urinary excretion of sodium(two days)
  • Urinary osmolarity(two days)
  • Urinary excretion of sodium-chloride symporter(two days)
  • pulse(two days)
  • middle arterial pressure(two days)

研究者

发起方
Regional Hospital Holstebro
申办方类型
Other
责任方
Principal Investigator
主要研究者

Erling Bjerregaard Pedersen

Professor, MD

Regional Hospital Holstebro

研究点 (1)

Loading locations...

相似试验